Abstract 9933: The "Respiratory-First" Masquerader: Late-Onset Pompe Disease Presenting as Bilateral Phrenic Nerve Palsy
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.9933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Hargun Ratol und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction: Late-onset Pompe disease (LOPD) presents significant diagnostic challenges due to its heterogeneous presentation, which can mimic other neuromuscular disorders and lead to considerable clinical delays. While LOPD typically manifests as a slowly progressive proximal myopathy, a "respiratory first" variant can exhibit pulmonary weakness prior to limb involvement. This disease is caused by an autosomal recessive deficiency in the lysosomal enzyme acid alpha-glucosidase (GAA), leading to systemic glycogen accumulation. Patient Information (De-identified): A 29-year-old male presented with a four-month history of progressively increasing pan-body weakness, severe exhaustion, and daytime drowsiness. Leading up to hospitalization, he experienced severe shortness of breath at rest. His family history was notable for a father who experienced unexplained phrenic nerve palsy. Clinical Findings: Upon emergency arrival, the patient was in severe respiratory distress requiring intubation (GCS E4 V1 M5). Physical examination revealed acute paraparesis with motor power of 1/5 in both lower limbs, lower limb areflexia, bilateral extensor plantar responses, and an absence of diaphragmatic movement indicative of bilateral phrenic nerve palsies. Diagnostic Assessment: High-Resolution Computed Tomography (HRCT) imaging of the chest revealed bilateral lower lobe collapse and consolidation likely secondary to diaphragmatic immobility. An echocardiogram demonstrated normal left ventricular size and preserved systolic function (LVEF 60%), ruling out the cardiovascular involvement characteristic of infantile Pompe disease. Neurophysiological studies suggested a primary myopathy rather than a neuropathic process. A severely low serum alpha-glucosidase level of 0.55 nmol/hr/mL prompted targeted gene sequencing, which confirmed the diagnosis by identifying compound heterozygous mutations in the GAA gene (c.-32-13T>G and c.670C>T). Therapeutic Intervention(s): The patient received critical care and ventilatory support for acute respiratory failure. Immediate establishment of Enzyme Replacement Therapy (ERT) using recombinant human alpha-glucosidase was recommended as the definitive treatment strategy. Discussions: This case illustrates a uniquely severe "respiration first" phenotype of LOPD, highlighting that bilateral phrenic nerve palsy and areflexia can masquerade as primary neurogenic conditions. The critical diagnostic anchor was the paternal history of phrenic nerve palsy, which redirected clinical suspicion toward metabolic storage diseases. Clinicians must maintain a high index of suspicion for Pompe disease in young adults presenting with unexplained diaphragmatic weakness and respiratory failure, even when cardiac evaluations are normal. Prompt genetic screening is essential to facilitate early intervention with ERT.
Zitieren
APA
Ratol, H., kaur, G., Mehta, S., Kaur, J., & Gandh, A. S. (2026). Abstract 9933: The "Respiratory-First" Masquerader: Late-Onset Pompe Disease Presenting as Bilateral Phrenic Nerve Palsy. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.9933
Vancouver
Ratol H, kaur G, Mehta S, Kaur J, Gandh AS. Abstract 9933: The "Respiratory-First" Masquerader: Late-Onset Pompe Disease Presenting as Bilateral Phrenic Nerve Palsy. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.9933
BibTeX
@article{Ratol2026,
author = {Ratol, Hargun and kaur, Gursimranpreet and Mehta, Sanchit and Kaur, Japsimran and Gandh, Avi Singh},
title = {Abstract 9933: The "Respiratory-First" Masquerader: Late-Onset Pompe Disease Presenting as Bilateral Phrenic Nerve Palsy},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.9933}
}
EUVIMED